Join the Vytorin group to help and get support from people like you.
Vytorin News
Gaps Persist in Actual Versus Optimal Atherosclerotic Cardiovascular Disease Care
TUESDAY, Dec. 5, 2023 – Roughly half of patients with atherosclerotic cardiovascular disease (ASCVD) adopt optimal prevention strategies across racial and ethnic subgroups, according to a study...
FDA Medwatch Alert: FDA Requests Removal of Strongest Warning Against Using Cholesterol-Lowering Statins During Pregnancy; Still Advises Most Pregnant Patients Should Stop Taking Statins
What safety information is FDA announcing? The U.S. Food and Drug Administration (FDA) is requesting removal of its strongest warning against using cholesterol-lowering statin medicines in pregnant...
FDA Medwatch Alert: Statin Drugs - Drug Safety Communication: Class Labeling Change
ISSUE: FDA has approved important safety label changes for the class of cholesterol-lowering drugs known as statins. The changes include removal of routine monitoring of liver enzymes from drug...
New FDA Approved Labeling For Vytorin (ezetimibe/simvastatin) Includes Results From the Study of Heart and Renal Protection (SHARP) in Patients With Moderate to Severe Chronic Kidney Disease
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Jan 25, 2012 - Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has...
FDA Medwatch Alert: Zocor (simvastatin): Label Change - New Restrictions, Contraindications, and Dose Limitations
Simvastatin sold under the brand-name Zocor, as a single-ingredient generic product, and sold in combination with ezetimibe as Vytorin and in combination with niacin as Simcor [UPDATED 12/15/2011]...
FDA Medwatch Alert: Zocor (simvastatin): Label Change - New Restrictions, Contraindications, and Dose Limitations
Simvastatin sold under the brand-name Zocor, as a single-ingredient generic product, and sold in combination with ezetimibe as Vytorin and in combination with niacin as Simcor [Posted 06/08/2011]...
FDA Medwatch Alert: Statin drugs and amyotrophic lateral sclerosis (ALS)
[Posted 09/30/2008] An FDA analysis provides new evidence that the use of statins does not increase incidence of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease often referred to as...
FDA Medwatch Alert: Ezetimibe/Simvastatin (Vytorin); Simvastatin (Zocor); and Ezetimibe (Zetia)
[Posted 08/21/2008] FDA informed healthcare professionals that the Agency is investigating a report from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial of a possible association...
FDA Medwatch Alert: Simvastatin Used With Amiodarone
[Posted 08/08/2008] FDA notified healthcare professionals of the risk of muscle injury, rhabdomyolysis, which can lead to kidney failure or death, when simvastatin is used with amiodarone. This risk...
FDA Medwatch Alert: Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor)
[Posted 01/25/2008] FDA provided healthcare professionals with an early communication about an ongoing data review for Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
High Cholesterol - Familial Heterozygous, High Cholesterol, High Cholesterol - Familial Homozygous